By Chris Wack
4D Molecular Therapeutics Inc. said it received a notice of termination of the collaboration and license agreement by 4D-110 licensee Roche resulting in full rights to 4D-110 for choroideremia reverting to 4D Molecular.
The company said Roche requested that 4D Molecular end the Roche-funded 4D-110 trial in advanced choroideremia patients as a result of Roche's assessment of a change in the risk-benefit profile.
Roche sent a notice of termination without cause effective Sept. 16, with 4D Molecular regaining full rights to 4D-110.
4D Molecular said it hasn't changed its position on the potential of 4D-110 for choroideremia, and intends to continue clinical development. The company said it plans to submit to the Food and Drug Administration safety and efficacy data from the completed Phase 1 clinical trial along with a new clinical study protocol as soon as possible.
The company said it will conclude the Roche-funded clinical trial under the collaboration and plans to subsequently transfer previously treated patients onto a company-sponsored long-term follow-up study to continue monitoring biologic activity endpoints, safety and tolerability.
4D Molecular Therapeutics shares were down 7% to $23 in premarket trading.
Write to Chris Wack at firstname.lastname@example.org
(END) Dow Jones Newswires